Clinical Trial Update: TAF for HIV-HBV With Renal Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating tenofovir alafenamide (TAF) for HIV and Hepatitis B coinfection in patients with renal dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Hepatitis B

Drugs mentioned

• Tenofovir alafenamide (tenofovir alafenamide)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: HIV and Hepatitis B Coinfection | Phase 2 | Status: COMPLETED